Capricor Therapeutics
CAPR
177 hedge funds and large institutions have $1.03B invested in Capricor Therapeutics in 2026 Q1 according to their latest regulatory filings, with 71 funds opening new positions, 58 increasing their positions, 35 reducing their positions, and 22 closing their positions.
223% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 22
126% more call options, than puts
Call options by funds: $119M | Put options by funds: $52.8M
66% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 35
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
34% more funds holding
Funds holding: 132 → 177 (+45)
30% more capital invested
Capital invested by funds: $791M → $1.03B (+$237M)
1.16% less ownership
Funds ownership: 59.98% → 58.82% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
+$54.2M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$45.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$36M |
| 4 |
BlackRock
New York
|
+$15.2M |
| 5 |
Jane Street
New York
|
+$15.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$27.1M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$23.2M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$18.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$9.67M |
| 5 |
Millennium Management
New York
|
-$8.69M |
CAPR Hedge Fund Activity: Q1 2026 in Review
177 of the 8,187 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q1 2026, worth a combined $1.03B — up 30% from $791M a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new CAPR positions and 22 closed out — a net gain of 49 holders — while 58 added to existing stakes and 35 trimmed.
The largest buyer was Suvretta Capital Management, adding an estimated $54.2M. The largest seller was Point72 Asset Management, cutting an estimated $27.1M.
- 177 institutional investors held Capricor Therapeutics (CAPR) as of Q1 2026, up from 132 in Q4 2025.
- Funds reported $1.03B of Capricor Therapeutics stock for Q1 2026, up 30% quarter-over-quarter.
- 71 funds opened new Capricor Therapeutics positions in Q1 2026 and 22 closed out, a net change of +49 holders.
- The largest Capricor Therapeutics buyer in Q1 2026 was Suvretta Capital Management, an estimated $54.2M added.
- The largest Capricor Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $27.1M sold.
Based on aggregated 13F filings for Q1 2026.